Olaptesed pegol is under clinical development by TME Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Olaptesed pegol’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 15 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olaptesed pegol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Olaptesed pegol overview

Olaptesed pegol (NOX-A12) is under development for the treatment of  metastatic pancreatic cancer, solid tumors including glioblastoma multiforme, glioma, metastatic colorectal cancer, pancreatic ductal adenocarcinoma and unspecified indication. The drug candidate is administered intravenously. NOX-A12 acts by targeting stromal cell-derived factor-1 (SDF-1). The drug candidate incorporates Spiegelmers technology platform. It was also under development for the treatment of hematopoietic stem cell transplantation, lupus nephritis, diabetic nephropathy, relapsed B-cell chronic lymphocytic leukemia (CLL) refractory/relapsed multiple myeloma and non-small cell lung cancer.

TME Pharma overview

TME Pharma formerly Noxxon Pharma, a subsidiary of TME Pharma NV, is a clinical and anti-cancer drug development company. It offers pipeline products such as NOX-E36 a target multiple tumor microenvironment chemokine and NOX-A12 a combination therapy for multiple cancer. The company also develops therapeutics for the treatment of tumor defenses, immunotherapy pancreatic cancer, metastatic pancreatic and colorectal cancer; glioblastoma, multiple myeloma and chronic lymphocytic leukemia and brain cancer. Noxxon’s Spiegelmer technology platform provides discovery capacities to generate additional leads under preclinical investigation. It is involved in tumor microenvironment approach for the cancer treatment. The company has collaborations with pharmaceutical, academic investigators, and research organizations. TME Pharma is headquartered in Berlin, Germany.

Quick View Olaptesed pegol LOA Data

Report Segments
  • Innovator
Drug Name
  • Olaptesed pegol
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Metabolic Disorders
  • Oncology
  • Undisclosed
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.